Form 4: Neumora Therapeutics Director Burow Reprices Stock Options

Kristina Burow, a director at Neumora Therapeutics, Inc., reports changes in beneficial ownership due to the repricing of stock options.

Summary

• Kristina Burow, a director of Neumora Therapeutics, filed a Form 4 detailing changes in her beneficial ownership of the company's securities.
• The filing reports the repricing of two stock option grants originally with exercise prices of $17 and $9.95 to a new exercise price of $1.69, subject to stockholder approval.
• The repricing affects options for 46,455 and 28,571 shares, respectively.
• The repriced options vest over time, with one grant vesting monthly from September 14, 2023, and the other vesting on the earlier of June 13, 2025, or the next Annual Meeting following June 13, 2024.
• The repricing is contingent on stockholder approval and Burow's continued service through August 13, 2026.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock option repricing. The sentiment is neutral as it simply reports facts without expressing positive or negative views.

Risks

• The stock option repricing is contingent on stockholder approval, and if not approved, the original terms of the options will remain in effect.
• The repricing is also contingent on the Reporting Person remaining in service to the Issuer through August 13, 2026.

Future Outlook

The repricing of the stock options is subject to stockholder approval, which will determine the final terms of the options.

Industry Context

Stock option repricing is a tool companies sometimes use to re-incentivize employees or board members when the stock price has declined significantly since the original grant date. It aims to restore the value of the options and encourage continued service and performance.

Stakeholder Impact

• The repricing of stock options could impact shareholder value depending on the future performance of the company's stock.
• The repricing is intended to incentivize the director, potentially aligning her interests with those of the shareholders.

Next Steps

• The company needs to obtain stockholder approval for the stock option repricing.

Key Dates